Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Subscribe To Our Newsletter & Stay Updated